Modulation of Prostate Cancer Cell Behavior Through Acetylsalicylic Acid-Treated Prostate Epithelial Cell-Derived
Dilşad Özerkan1, Selda Durukan1, Mahsa Koucheki1
1Department of Genetic and Bioengineering, Faculty of Engineering and Architecture, Kastamonu University, Kastamonu, Turkey.
Cell Biochemistry and Function
|August 5, 2026
Summary
Acetylsalicylic acid (ASA) shows promise in prostate cancer prevention. ASA-treated cells release factors that reduce prostate cancer cell viability and migration, suggesting a therapeutic role.
Area of Science:
- Oncology
- Pharmacology
Background:
- Acetylsalicylic acid (ASA), also known as aspirin, possesses analgesic, anti-inflammatory, and antiplatelet effects.
- Emerging research indicates ASA may lower the risk of certain cancers, including prostate cancer.
Purpose of the Study:
- To investigate the impact of ASA-treated prostate epithelial cells on prostate cancer cell proliferation and migration.
- To explore the potential of ASA as a chemopreventive and therapeutic agent for prostate cancer.
Main Methods:
- Prostate epithelial cells (RWPE-1) were treated with varying ASA concentrations.
- Conditioned media (CM) from treated and untreated cells were applied to prostate cancer cells (PC-3).
- Cell viability (MTT assay), migration (wound-healing assay), and colony formation were assessed.
Main Results:
- Non-cytotoxic ASA concentrations (e.g., 50 μM) did not harm RWPE-1 cells.
- CM from ASA-treated RWPE-1 cells significantly reduced PC-3 cell viability (to 60% with 50 μM ASA) and inhibited migration.
- ASA alters the prostate epithelial cell secretome, impacting cancer cell behavior.
Conclusions:
- ASA exposure modifies the secretome of prostate epithelial cells.
- These modifications lead to decreased prostate cancer cell viability and motility.
- ASA demonstrates potential as a chemopreventive and therapeutic agent for prostate cancer.
